None
Quote | Morphosys Ag Sp/Adr (OTCMKTS:MPSYY)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $27.93 |
High: | $N/A |
Low: | $N/A |
Volume: | 9 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Morphosys Ag Sp/Adr (OTCMKTS:MPSYY)
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Message Board Posts | Morphosys Ag Sp/Adr (OTCMKTS:MPSYY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Sp/Adr Company Name:
MPSYY Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. on track - David Trexler hired as President, MorphoSys US Inc.; build-up of c...